U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023848) titled 'PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors' on May 11.
Brief Summary: The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibody fragments in diagnosis and screening of HER2-positive cancer patients.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Gastric Cancer (GC)
Urothelial Carcinoma (UC)
Intervention:
DRUG: 89Zr-LNCab104
89Zr-LNCab104 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
DRUG: 89Zr-LNCab103
89Zr-LNCab103 is administered throu...